Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Howe Jill Ann
March 10, 2024 at 04:43 am EDT
Share
SEC Form 4
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB APPROVAL
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
OMB Number:
3235-0287
Estimated average burden
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
hours per response:
0.5
or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person*
Howe Jill Ann
(Last)
(First)
(Middle)
C/O LINEAGE CELL THERAPEUTICS
2173 SALK AVENUE, SUITE 200
(Street)
CARLSBAD
CA
92008
(City)
(State)
(Zip)
2.
Issuer Name and Ticker or Trading Symbol
5.
Relationship of Reporting Person(s) to Issuer
Lineage Cell Therapeutics, Inc.[ LCTX ]
(Check all applicable)
Director
10% Owner
X
Officer (give title
Other (specify
3.
Date of Earliest Transaction (Month/Day/Year)
below)
below)
03/07/2024
Chief Financial Officer
4.
If Amendment, Date of Original Filed (Month/Day/Year)
6.
Individual or Joint/Group Filing (Check Applicable
Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting
Person
Rule 10b5-1(c) Transaction Indication
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)
2. Transaction
2A. Deemed
3.
4. Securities Acquired (A) or
5. Amount of
6. Ownership
7. Nature of
Date
Execution Date,
Transaction
Disposed Of (D) (Instr. 3, 4 and 5)
Securities
Form: Direct
Indirect
(Month/Day/Year)
if any
Code (Instr.
Beneficially
(D) or Indirect
Beneficial
(Month/Day/Year)
8)
Owned Following
(I) (Instr. 4)
Ownership
Reported
(Instr. 4)
Code V
Amount
(A) or
Price
Transaction(s)
(D)
(Instr. 3 and 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. One quarter of the options shall vest on March 7, 2025, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
/s/ Jill A. Howe
03/08/2024
** Signature of Reporting Person
Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Lineage Cell Therapeutics Inc. published this content on
10 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
10 March 2024 08:42:13 UTC.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.